COLLIBRI is a consortium that looks to accelerate progress in the field of inflammatory bowel disease through the use of protein biomarkers, engaging academic and industrial partners to share both clinical samples and the data obtained from relevant studies. The aim is to generate novel insights into disease pathogenesis and find novel biomarker signatures at the proteomic level.
The current efforts are focused on addressing questions of immediate interest to academia and industry, using protein data generated on the Olink platform. Please visit www.olink.com/collibri for more details. COLLIBRI is also organizing its first meeting with the different academic centers and interested partners from industry, in conjunction with the 15th ECCO Congress in Vienna, Austria from February 12-15, 2020 – see more here.